Detalles de la búsqueda
1.
A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation.
Hepatology;
77(3): 715-728, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36056902
2.
HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol;
21(12): 3019-3029.e5, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37061107
3.
Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Gastroenterology;
163(4): 937-949.e2, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35753383
4.
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.
J Intern Med;
293(5): 648-655, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36843323
5.
Impact on follow-up strategies in patients with primary sclerosing cholangitis.
Liver Int;
43(1): 127-138, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35535655
6.
Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type.
Scand J Gastroenterol;
58(8): 874-882, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36788656
7.
Primær skleroserende kolangitt.
Tidsskr Nor Laegeforen;
143(17)2023 11 21.
Artículo
en Noruego
| MEDLINE | ID: mdl-37987062
8.
The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
BMC Med;
20(1): 378, 2022 10 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36199139
9.
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial.
J Intern Med;
292(3): 477-491, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35411981
10.
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
JAMA;
325(17): 1744-1754, 2021 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33944876
11.
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
JAMA;
326(23): 2375-2384, 2021 12 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34932077
12.
Diagnosis and treatment of autoimmune hepatitis. / Diagnostikk og behandling av autoimmun hepatitt.
Tidsskr Nor Laegeforen;
141(10)2021 06 29.
Artículo
en Noruego
| MEDLINE | ID: mdl-34182737
13.
[The FIB-4 test as a decision-making tool]. / FIB-4-testen som beslutningsverktøy.
Tidsskr Nor Laegeforen;
143(5)2023 03 28.
Artículo
en Noruego
| MEDLINE | ID: mdl-36987901
14.
Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease.
J Hepatol;
66(1): 116-122, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27647428
15.
We need a new strategy for liver disease. / Vi trenger en ny strategi for leversykdom.
Tidsskr Nor Laegeforen;
142(3)2022 02 15.
Artículo
en Noruego
| MEDLINE | ID: mdl-35170917
16.
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials.
Lancet Rheumatol;
6(4): e226-e236, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38402891
17.
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study.
RMD Open;
10(2)2024 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38599653
18.
Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease.
Clin Gastroenterol Hepatol;
11(5): 517-23, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23333218
19.
T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis.
JCI Insight;
8(12)2023 06 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-37159281
20.
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study.
Lancet Rheumatol;
5(1): e36-e46, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36415604